Radar · Oncology in Paris
Best Oncology Companies in Paris, France
The 42 best Oncology companies in Paris, France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Cellectis.
By Rohit KhannaTrends & Stories
42companies tracked
$956.4Mdisclosed funding
0unicorns
24have raised
FLIAR INTELLIGENCE · ONCOLOGY × PARIS
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
86%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
135kcombined LinkedIn audience
64%of audience held by top 3
2companies hiring publicly (12 mo)
Ranked: Best Oncology companies in Paris
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Cellectis Developer of cancer immunotherapies based on gene-edited CAR T-cells 64Patents top 20%Funding top 25%Product top 29%Innovation top 30% All 11 signals ▾Patentstop 20% Fundingtop 25% Producttop 29% Innovationtop 30% Newstop 33% Markettop 38% Moattop 41% Globaltop 45% Growthtop 48% Talentbottom 49% Techbottom 46% Patents: 1,579 patents matched (strict assignee match) · 326 filings since 2022 vs 610 in 2017-21 Funding: Raised $267M across 3 rounds · 3 rounds over 12 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $267M | 27 mo ago | 236 | Andre Choulika Chief Executive Officer | ExpressionEngineApple iCloud MailMicrosoft 365+14 | 1,572 patents Engineered CAR‑T and gene‑edited immune cells for cancer immunotherapy. | — |
| 2 | Enterome Developer of immunomodulatory drugs targeting cancer and immune diseases | $130M | 74 mo ago | 70 | — | — | 188 patents Microbiome-derived antigenic peptides for cancer immunotherapy and B‑cell malignancy treatment | — |
| 3 | Mnemo Therapeutics Developer of cell therapy platforms for tumors and blood cancer | $91M | 62 mo ago | 56 | Alain Maiore Co-Founder & ex-CEO | — | 58 patents Neoantigen peptide-based cancer immunotherapy and epigenetic modulation of immune cells | — |
| 4 | AB Science Developer of tyrosine kinase inhibitors for multiple disease indications 42Funding top 20%Patents top 21%Innovation top 28%Moat top 28% All 9 signals ▾Fundingtop 20% Patentstop 21% Innovationtop 28% Moattop 28% Newstop 33% Growthtop 45% Techbottom 41% Globalbottom 38% Marketbottom 21% Funding: Raised $83.2M across 9 rounds · 9 rounds over 9 yrs (1.0/yr) Patents: 461 patents matched (strict assignee match) · 78 filings since 2022 vs 86 in 2017-21 rank vs industry peers · Fliar Intelligence Index 42/100 | $83M | 3 mo ago | 3 | — | WordPressPleskMySQL+22 | 454 patents Small‑molecule kinase and tubulin inhibitors for hematologic cancers and neurodegenerative disorders | — |
| 5 | TheraVectys Developer of vaccines to treat infectious diseases and cancer caused by HTLV-1 infection | $62M | 66 mo ago | 19 | Ye Tian CEO | — | 176 patents Lentiviral vector platforms for viral antigen vaccines and cancer immunotherapy | — |
| 6 | Carthera Devices focused on the treatment of brain tumors | $55M | 32 mo ago | 20 | — | WordPressCart FunctionalityMySQL+16 | 96 patents Implantable ultrasonic/acoustic brain imaging and therapy devices with coupling fault detection | — |
| 7 | Egle Therapeutics Provider of T cells based therapeutics for oncology and autoimmune diseases 45Funding top 34%Talent top 38%Moat top 39%Patents top 40% All 7 signals ▾Fundingtop 34% Talenttop 38% Moattop 39% Patentstop 40% Innovationbottom 49% Marketbottom 44% Globalbottom 43% Funding: Raised $46.6M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $47M | 17 mo ago | 28 | Eliane Piaggio Co-Founder | — | 11 patents Engineered cytokine variants and fusion immunotherapeutics for cancer immunotherapy | — |
| 8 | Genticel Developer of immunotherapies to treat infectious diseases and cervical cancer using CyaA vector technology | $41M | 160 mo ago | 32 | — | — | 50 patents Bacterial toxin-derived chimeric proteins for vaccine and immunotherapy antigen delivery | — |
| 9 | Hybrigenics R&D for new targets & therapies against proliferative diseases | $28M | 203 mo ago | 200 | — | — | 216 patents Antibody therapeutics and vitamin D analog small‑molecule immuno‑oncology agents | — |
| 10 | Advesya Developer of therapies for the treatment of cancer and autoimmune diseases | $26M | 55 mo ago | — | Ksenija Pavletic Chief Executive Officer | — | 8 patents Antibody‑drug conjugates and CAR‑T cells targeting IL‑1RAP for cancer therapy | — |
| 11 | Qubit Pharmaceuticals Developer of drugs for the treatment of cancer and inflammatory diseases | $25M | 48 mo ago | 50 | Jay Ponder Co-Founder | WebflowApple iCloud MailGoogle Workspace+14 | 15 patents Quantum-enabled molecular modeling and advanced quantum circuit design for chemistry applications | — |
| 12 | SquareMind Developer of robotic medical equipment for skin cancer detection 50AI top 15%Patents top 28%Innovation top 32%Moat top 32% All 9 signals ▾AItop 15% Patentstop 28% Innovationtop 32% Moattop 32% Fundingtop 38% Talentbottom 49% Globalbottom 43% Techbottom 41% Marketbottom 26% AI: Holds AI/ML patents (G06N-family CPC) Patents: 57 patents matched (strict assignee match) · 48 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $21M | 4 mo ago | 10 | Ali Khachlouf Co-Founder & CEO | PrismicNode.jsVue.js+7 | 57 patents Robotic arm guidance systems and medical imaging differential marker generation technologies. | — |
| 13 | Iktos Artificial Intelligence for new drug design | $16M | 41 mo ago | 55 | Nicolas Do Huu Co-Founder & CTO | PrismicNode.jsThree.js+14 | — | — |
| 14 | Rarecells Developer of noninvasive tests for earlier cancer diagnoses | $13M | 56 mo ago | 22 | — | — | 20 patents Rare cell isolation, filtration, and liquid biopsy biomarker analysis for cancer diagnostics | 1 partnership |
| 15 | Nanobiotix Developer of nanotherapeutics designed to enhance cancer treatment via radioenhancement | $11M | 32 mo ago | 102 | — | DrupalApple iCloud MailMicrosoft 365+24 | 478 patents Nanoparticle-based therapeutic vaccines and drug delivery for cancer and neurological disorders | — |
| 16 | DAMAE Medical Developer of imaging diagnostic device for skin cancer | $10M | 54 mo ago | 32 | Anais Barut Co-Founder & CEO | Google MapsYouTubeBootstrap+7 | 65 patents Optical microscopy devices and AI-driven tissue region-of-interest imaging for dermatology and histopathology. | 1 job opening |
| 17 | Oncovita Developer of virus-derived vaccine technology to treat cancer | $9M | 33 mo ago | 2 | Frederic Tangy Co-Founder | — | — | 1 partnership |
| 18 | HEPTA Medical Developer of minimally invasive non-surgical treatment for cancer | $6M | 23 mo ago | 7 | Thomas Bancel CEO | — | — | — |
| 19 | ORPHELIA Pharma Developer of therapies for treating pediatric neurology, pediatric oncology, and hematology | $4M | 80 mo ago | 9 | Hugues Bienayme Founder & CEO | — | — | — |
| 20 | Stimunity Virus like particles for non-responsive cancers | $4M | 75 mo ago | 4 | — | — | 6 patents Therapeutic peptide/antibody compositions for cancer immunotherapy applications | — |
| 21 | Honing Biosciences Developer of cell-based therapies to treat cancer and chronic diseases | $2M | 73 mo ago | — | Abdelkader Bousabaa Founder | — | 13 patents Therapeutic single-domain antibodies (nanobodies) targeting HER2 and protein trafficking control | — |
| 22 | IPSirius Developer of immunotherapies for cancer treatment | $2M | 47 mo ago | — | Annelise Griscelli Co-Founder | — | — | — |
| 23 | Biomunex Developer of antibody therapeutics for the treatment of cancer | $2M | 64 mo ago | 14 | Pierre-Emmanuel Gerard President and Founder | WordPressMySQLPHP+16 | — | 2 job openings · 2 internships |
| 24 | Jalon Therapeutics Developer of therapeutics for cancer treatment | $1M | 45 mo ago | 6 | Jean-Luc Poyet Co-Founder | — | — | — |
Top 12 Oncology companies in Paris
#1
Public · Paris, Ile de France · founded 2001 · 3 employees$83.2Mraised▾
Public · Paris, Ile de France · founded 2001 · 3 employees
Developer of tyrosine kinase inhibitors for multiple disease indications. The company's lead candidate drugs are masitinib, a highly selective tyrosine kinase inhibitor, and AB8939, a new generation microtubule destabilizer for oncology, neurodegenerative and inflammatory indications.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 20%Patents
top 21%Innovation
top 28%Moat
top 28%News
top 33%Growth
top 45%Funding: Raised $83.2M across 9 rounds · 9 rounds over 9 yrs (1.0/yr) · Last round Post IPO (May 2026)
Patents: 461 patents matched (strict assignee match) · 78 filings since 2022 vs 86 in 2017-21 · Latest publication 2025
Innovation: 461 patents (top 5% of patent-holders) · 78 filings since 2022 vs 86 in 2017-21
Funding rounds
- May 2026Post IPO$3M
- Oct 2025Post IPO$3.3M
- Jul 2025Post IPO$2.3M
- May 2025Post IPO$2M
Tech stack
Contact Form 7Core-JsGoogle AnalyticsGoogle Font ApiGsapIsotope
#2
Seed · Paris, Ile de France · founded 2019 · 10 employees$20.6Mraised▾
Seed · Paris, Ile de France · founded 2019 · 10 employees
Developer of robotic medical equipment for skin cancer detection. It offers autonomous robots equipped with third-dimension construction software that capture data by full-body mapping to detect skin cancer. It allow physicians to track the growth of moles on the body using off-the-shelf robots.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
AI
top 15%Patents
top 28%Innovation
top 32%Moat
top 32%Funding
top 38%Talent
bottom 49%AI: Holds AI/ML patents (G06N-family CPC)
Patents: 57 patents matched (strict assignee match) · 48 filings since 2022 vs 9 in 2017-21 · Latest publication 2026
Innovation: 57 patents (top 44% of patent-holders) · 48 filings since 2022 vs 9 in 2017-21 · Deep-tech classification: Tech Hardware
Funding rounds
- Apr 2026Seed$18M
- Jul 2022Grant (prize money)$2.6M
- 2022Grant (prize money)—
- Seed—
Founders & team
Investors
EIC Fund, Europa, Sonder Capital, Bpifrance, Adamed Technology, Teampact Ventures
Tech stack
Amazon Web ServicesHstsLenisNode.JsNuxt.JsOpen Graph
#3
Series A · Paris, Ile de France · founded 2020 · 28 employees$46.6Mraised▾
Series A · Paris, Ile de France · founded 2020 · 28 employees
Provider of T cells-based therapeutics for oncology and autoimmune disease. The company offers computational-based IL-2 modified variants and translational-based therapeutic Treg targets to restore the immune response.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 34%Talent
top 38%Moat
top 39%Patents
top 40%Innovation
bottom 49%Market
bottom 44%Funding: Raised $46.6M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) · Last round Grant (prize money) (Mar 2025)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 4/10 · IP moat: 11 patents · Soonicorn
Audience (LinkedIn): 5k LinkedIn followers — 3.4% of this cohort's audience
Funding rounds
- Mar 2025Grant (prize money)$10.1M
- Oct 2021Series A$46.6M
Founders & team
Investors
Bioqube Ventures, Takeda, Fund+, Life Sciences Partners, Bpifrance, T1D Fund
#4
Public · Paris, Ile de France · founded 1999 · 236 employees$267.4Mraised▾
Public · Paris, Ile de France · founded 1999 · 236 employees
Developer of cancer immunotherapies based on gene-edited CAR T-cells. The company is developing products based on TALEN, its proprietary gene-editing technology, and PulseAgile, it's pioneering electroporation system to target cancer cells. It develops UCART products to treat multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), multiple myeloma (MM), Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL).
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Patents
top 20%Funding
top 25%Product
top 29%Innovation
top 30%News
top 33%Market
top 38%Patents: 1,579 patents matched (strict assignee match) · 326 filings since 2022 vs 610 in 2017-21 · Latest publication 2026
Funding: Raised $267M across 3 rounds · 3 rounds over 12 yrs (0.2/yr) · Last round Post IPO (May 2024)
Product: 0 product launch events in 12 mo · 6 distinct product lines · Company stage: Public
Audience (LinkedIn): 49k LinkedIn followers — 36.0% of this cohort's audience
Funding rounds
- May 2024Post IPO$140M
- Nov 2023Post IPO$105M
- Mar 2014Post IPO$22.4M
Founders & team
Investors
AstraZeneca, Orbimed, VenBio, Ridgeback Capital Management, Aquilo Capital Management, Merlin Nexus
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCodeigniterCookiebotDocusign
#5
Series B · Paris, Ile de France · founded 2010 · 20 employees$55.1Mraised▾
Series B · Paris, Ile de France · founded 2010 · 20 employees
CarThera develops medical devices, using ultrasound technology, focused on the treatment of brain tumors. The company is developing two medical devices SonoProbe - for the thermal ablation of brain tumors, and SonoCloud - for improving the efficacy of chemotherapy.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 8k LinkedIn followers — 5.8% of this cohort's audience
Funding rounds
- Dec 2023Series B$4.8M
- Jun 2023Series B$40M
- Oct 2020Grant (prize money)$2.4M
- Dec 2018Series B$10.2M
Investors
Panakes Partners, Supernova Invest, Sham, Unorthodox Ventures, Heritiers Saint-Genys, Bouscas Med
Tech stack
Cart FunctionalityWordpressMysqlPhpYoast SeoApache Http Server
#6
Series A · Paris, Ile de France · founded 2018 · 7 employees$6.3Mraised▾
Series A · Paris, Ile de France · founded 2018 · 7 employees
Developer of minimally invasive non-surgical treatment for cancer. The company is developing an endoscopically delivered ablation catheter that uses temperature-based feedback and real-time dosing to precisely target and ablates pulmonary nodules, the precursor of lung cancer.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Funding rounds
- Sep 2024Series A$6.3M
Founders & team
Investors
Bpifrance, M&L Healthcare, Cléry
#7
Series E · Paris, Ile de France · founded 2008 · 70 employees$129.7Mraised▾
Series E · Paris, Ile de France · founded 2008 · 70 employees
Developer of immunomodulatory drugs targeting cancer and immune diseases. The company develops drugs based on the ability to de-code the gut microbiome’s interaction with the immune system. The company has developed two technology platforms which include OncoMimics therapeutic cancer vaccines, and EndoMimics an oral bioactive to treat inflammatory and autoimmune diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 17k LinkedIn followers — 12.6% of this cohort's audience
Funding rounds
- Jun 2020Series E$52.3M
- Jan 2018Conventional Debt$48.1M
- Jan 2018Series D$38.5M
- Apr 2016Series C$16.4M
Investors
Omnes Capital, Seventure Partners, Lundbeck Foundation, Symbiosis, Takeda, Nestlé Health Science
#8
Public · Paris, Ile de France · founded 2003 · 102 employees$11Mraised▾
Public · Paris, Ile de France · founded 2003 · 102 employees
Developer of nanotherapeutics designed to enhance cancer treatment via radioenhancement. Its lead candidate is designed to increase the dose of radiotherapy absorbed by tumor cells. This is intended to destroy the target tumor and prime the immune response. The company collaborates with institutions to develop therapies for cancer.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 21k LinkedIn followers — 15.3% of this cohort's audience
Activity: 1 partnerships announced in 12 mo
Funding rounds
- Dec 2023Post IPO$4.8M
- Mar 2019Conventional Debt$15.9M
- Oct 2018Conventional Debt$18.9M
- Jul 2018Conventional Debt$16.4M
Investors
European Investment Bank, Europa, Johnson & Johnson Innovation, Seventure Partners, Masseran Gestion, Karista
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services
#9
Series A · Paris, Ile de France · founded 2018 · 56 employees$90.9Mraised▾
Series A · Paris, Ile de France · founded 2018 · 56 employees
Developer of cell therapy platforms for tumors and blood cancers. The company has EnfiniT targeting and next-generation chimeric antigen receptors T cell therapy platform. It identifies antigens with tumor specificity that are present in cancer cells.
Funding rounds
- Jun 2021Series A$90.9M
Founders & team
Investors
Casdin Capital, Sofinnova Partners, Emerson Collective, Alexandria, Redmile Group
#10
Series D · Paris, Ile de France · founded 2005 · 19 employees$62.1Mraised▾
Series D · Paris, Ile de France · founded 2005 · 19 employees
Developer of vaccines to treat infectious diseases and cancer caused by HTLV-1 infection. By using the lentiviral immunotherapy platform the company has developed therapeutic vaccines for HIV, Hepatitis-B, Tuberculosis, and Adult T-cell Lymphoma-Leukaemia (ATL) induced by Human T-Lymphotropic Virus Type I (HTLV-1) infection.
Funding rounds
- Feb 2021Series D$20M
- Apr 2017Series C$5.8M
- Jan 2015Grant (prize money)$2.1M
- Oct 2013Series C$19.9M
Founders & team
Investors
FGP Capital, iXLife Capital, Bpifrance
Tech stack
WordpressMysqlPhpWindows ServerWordpress Super CacheDivi
#11
Series A · Paris, Ile de France · founded 2015 · 2 employees$8.8Mraised▾
Series A · Paris, Ile de France · founded 2015 · 2 employees
Developer of virus-derived vaccine technology to treat cancer. It offers Measovir platform that utilizes anti-cancer and immunogenic properties to produce effective new cancer treatments and vaccines.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Activity: 1 partnerships (incl. Infinitusbio.AI and ITJ teams) announced in 12 mo
Funding rounds
- Nov 2023Series A$8.8M
Founders & team
Investors
Bpifrance
#12
Seed · Paris, Ile de France · founded 2020 · 50 employees$24.6Mraised▾
Seed · Paris, Ile de France · founded 2020 · 50 employees
Developer of drugs for the treatment of cancer and inflammatory diseases. The company uses software and AI-enhanced medicinal chemistry to develop novel drug candidates in the areas of oncology, inflammation, and pandemics response.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 12k LinkedIn followers — 8.8% of this cohort's audience
Activity: 2 partnerships (incl. Centre for Quantum Technologies) announced in 12 mo
Funding rounds
- Sep 2022Grant (prize money)$2.5M
- Jun 2022Seed$17.2M
- Jun 2020Grant (prize money)—
Founders & team
Investors
XAnge, Quantonation, Omnes Capital, EIT Health, EIC Fund
Tech stack
Apple Icloud MailCdnjsCloudflareGoogle Font ApiGoogle Hosted LibrariesGoogle Workspace
Funding & investor landscape
$956.4Mtotal disclosed funding
24companies funded
73disclosed rounds
0rounds last 90 days
Most active investors
Bpifrance13 rounds
Omnes Capital3 rounds
Notable founders
Ali Khachlouf
Co-Founder & CEO · SquareMind
Eliane Piaggio
Co-Founder · Egle Therapeutics
Luc Boblet
Founder & CEO · Egle Therapeutics
Andre Choulika
Chief Executive Officer · Cellectis
Thomas Bancel
CEO · HEPTA Medical
Alain Maiore
Co-Founder & ex-CEO · Mnemo Therapeutics
Robert LaCaze
CEO · Mnemo Therapeutics
Ye Tian
CEO · TheraVectys
Frederic Tangy
Co-Founder · Oncovita
Jean Le Bigot
CEO · Oncovita
Jay Ponder
Co-Founder · Qubit Pharmaceuticals
Piquemal
Co-Founder · Qubit Pharmaceuticals
Prism market signals · France · country-scoped Prism corpus, 2,001,202 docs
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN PARIS · Health & Bio
How research on Oncology in Paris is moving
A read on the academic research around Oncology in Paris — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 216 papers.
216 papers · stance +0.51 · 32% breakthrough · 14% concern
top institutions
- Assistance Publique – Hôpitaux de Paris102
- Délégation Paris 531
- Université Paris-Saclay27
- Université Paris Cité24
- Université Paris Sciences et Lettres9
leading researchers
Guido Kroemer · Bernhard Mlecnik · Laurence Zitvogel · Lorenzo Galluzzi · Marie‐Caroline Dieu‐Nosjean · Oliver Kepp
prism intelligence · tone & topics
98% positive · 0% critical tone
BiotechnologyPharmaceuticalsClinical TrialsMedical ResearchHealthHealthcare
▲
Breakthroughs63 · 29%
▲ 15%→31% share
▲2.1× share momentum5 median citations76% since 2021mostly empirical
Breakthroughs are rising (15%→31% of field), led by Tumor microenvironment.
rising sub-themes (early→recent)
- Tumor microenvironment3→20
- Immune system1→13
- Immunotherapy2→10
- Stromal cell1→5
- Cell biology1→4
Newly emergingCancer research 0→18 · Cytotoxic T cell 0→6 · Immunogenic cell death 0→6
Landmark Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression · 3,923 cites
◆
Advancements105 · 49%
▼ 64%→45% share
▼0.7× share momentum10 median citations67% since 2021mostly empirical
Advancements are cooling (64%→45% of field), led by Immunotherapy.
rising sub-themes (early→recent)
- Immunotherapy6→39
- Immune system15→33
- Cancer research6→21
- Tumor microenvironment12→23
- Cancer immunotherapy5→14
Newly emergingTranscriptome 0→5 · Biomarker 0→4 · Immune checkpoint 0→4
Landmark Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota · 3,336 cites
▼
Concerns27 · 12%
▲ 9%→15% share
▲1.7× share momentum3 median citations85% since 2021mostly reviews
Concerns are rising (9%→15% of field), led by Immunotherapy.
rising sub-themes (early→recent)
- Immunotherapy1→13
- Immune system1→11
- Cancer immunotherapy1→4
Newly emergingTumor microenvironment 0→12 · Clinical trial 0→6 · Cancer research 0→5
Landmark The clinical role of the TME in solid cancer · 736 cites
Common questions
How many Oncology companies are there in Paris, France?
Radar tracks 42 indexable Oncology companies headquartered in Paris, France that meet our profile-completeness bar.
What is the total funding raised by Oncology companies in Paris, France?
The Oncology companies in Paris, France on this list have raised a combined $956.4M in disclosed equity funding across 24 funded companies.
Which is the highest-funded Oncology company in Paris, France?
Cellectis is the highest-funded Oncology company in Paris, France, with $267.4M in disclosed equity funding.
How many Oncology companies in Paris, France are funded?
24 of the 42 Oncology companies in Paris, France on this list have disclosed at least one equity funding round.
How many Oncology unicorns are there in Paris, France?
None of the Oncology companies in Paris, France on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Paris, France Oncology companies?
The most active investors in Paris, France Oncology companies on this list include Bpifrance, Europa, EIC Fund, Idinvest Partners, Kurma Partners.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.